Long Position on GILD @ $57.34 on 8/20/2013 (Momentum)

Gilead Sciences (GILD) discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.

Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation.

The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products.  

Shares have formed a bullish "cup & handle", following the release of its strong earnings, and higher share prices are expected for this stock.

52-Week Trading Range:  $27.93 - $64.04

Entry Point: $57.34

Stop Loss:  $54.45

Target Price:  $63.05

Updates

9/12/2013 10:27:47 AM

GILD reached our target price. If you elect to stay in the stock, raise your stop loss to $62.25 to protect your gains.

Position closed on 9/12/2013 at price of $63.05 with a 9.96% gain in 23 days.

Back to Portfolio